Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects

Journal of Clinical Endocrinology and Metabolism

Volumn 88, Issue 1, 2003, Pages 220-224

  Vilsbøll, Tina ^a,b,d   Agerso H ^c   Krarup, T ^a   Holst, J J ^b  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Ferring Pharmaceuticals AS   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BODY MASS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ELIMINATION; EXCRETION; FEMALE; FOOD INTAKE; HORMONE BLOOD LEVEL; HORMONE METABOLISM; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

AGED; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; OBESITY; OSMOLAR CONCENTRATION; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; REFERENCE VALUES;

EID: 0037241085     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2002-021053     Document Type: Article

References (21)

1. Holst JJ 1983 Gut glucagon, enteroglucagon, gut glucagon-like immunoreactivity, glicentin - current status. Gastroenterology 84:1602-1613
2. Orskov C, Holst JJ, Poulsen SS, Kirkegaard P 1987 Pancreatic and intestinal processing of proglucagon in man. Diabetologia 30:874-881
3. Orskov C, Holst JJ, Nielsen OV 1988 Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology 123:2009-2013
4. Kreymann B, Williams G, Ghatei MA, Bloom SR 1987 Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2:1300-1304
5. Deacon CF, Johnsen AH, Holst JJ 1995 Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80:952-957
6. Deacon CF, Pridal L, Klarskov L, Olesen M, Holst JJ 1996 Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol 271:E458-E464
7. Gutniak MK, Linde B, Holst JJ, Efendic S 1994 Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM. Diabetes Care 17:1039-1044
8. Nauck M, Stockmann F, Ebert R, Creutzfeldt W 1986 Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29:46-52
9. Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ 2001 Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50:609-613
10. Vilsboll T, Krarup T, Holst JJ 2002 Similar elimination rates of GLP-1 in obese type 2 diabetic patients and matched healthy subjects. Diabetes 51:A344
11. Vilsboll T, Toft-Nielsen MB, Krarup T, Madsbad S, Dinesen B, Holst JJ 2000 Evaluation of β-cell secretory capacity using glucagon-like peptide 1. Diabetes Care 23:807-812
12. Alberti KG, Zimmet PZ 1998 Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15: 539-553
13. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus 2002. Diabetes Care 25:S5-S20
14. Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ 1994 Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43:535-539
15. Gutniak MK, Larsson H, Heiber SJ, Juneskans OT, Holst JJ, Ahren B 1996 Potential therapeutic levels of glucagon-like peptide I achieved in humans by a buccal tablet. Diabetes Care 19:845-848
16. Gibaldi M, Perrier D 1982 Pharmacokinetics. In: Drugs and the pharmaceutical science. 2nd ed. Vol 15. New York: Marcel Dekker.
17. Deacon CF, Nauck MA, Meier J, Hucking K, Holst JJ 2000 Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 85:3575-3581
18. Hansen L, Deacon CF, Orskov C, Holst JJ 1999 Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 140:5356-5363
19. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W 1993 Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91:301-307
20. Zander M, Madsbad S, Madsen JL, Holst JJ 2002 Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet 359:824-830
21. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W 1993 Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36:741-744